They may also form the basis of potential pharmacological applications in Alzheimer’s disease and other conditions associated with cholinergic deficiency; they may be suitable candidates for the design of AChE inhibitor drugs and in research on neuromuscular transmission and synaptic physiology [155,156,157,160]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.